StemRIM's Shionogi-Partnered Stroke Drug Misses Its Primary Endpoint While a Rare-Disease Trial Delivers
Redasemtid, StemRIM's HMGB1-peptide drug licensed to Shionogi, missed its primary endpoint in a global stroke trial's no-reperfusion cohort, while a small four-patient trial in the rare skin disease dystrophic epidermolysis bullosa hit its mark with three ulcer closures; Shionogi now decides the stroke program's future.